8th APS International PharmSci Conference
05 September 2017 - 07 September 2017
APS International PharmSci is the leading UK Pharmaceutical Science conference and has firmly established itself as the premier pharmaceutical science event in the UK.
5-7 September 2017 will see the 8th APS International PharmSci Conference returning to the De Havilland Campus of the University of Hertfordshire in Hatfield. The theme of the conference in 2017 is 'Pharmaceutical Science without borders'.
The APS is pleased to announce Professor Abdul Basit as this year's Conference Science Chair.
De Havilland Campus, University of Hertfordshire, Hatfield, Herts, UK
http://www.ukpharmsci.org/default.asp
2nd European Prefilled Syringes Summit
06 September 2017 - 07 September 2017
After the success of our first European Prefilled Syringes Summit, we are pleased to announce the next edition which shall take place on the 6th & 7th September in Berlin, Germany.
ACI’s European Prefilled Syringes Summit will explore the advancements in regulatory guidelines, product development, manufacturing processes, risk mitigation , portfolio management and answer some infinite industry questions such as; how the industry is responding to disruptive technology, connectivity, speed to market, and next generation syringes. . There are several elements that pose a severe challenge to the growth of the global prefilled syringes market, the primary one being the high costs associated with temperature controlled packaging required for temperature-sensitive drugs. Other more traditional factors inhibiting the market include product recalls due to breakages and leachables, the potential risk of interaction between prefilled syringes and drugs, and needle stick prevention.
tbc Berlin, Germany
http://www.wplgroup.com/aci/event/european-prefilled-syringes-summit/
7th Pharmacovigilance, Drug Safety & Risk Management
13 September 2017 - 14 September 2017
This two day conference will enable attendees to streamline risk mitigation and improve drug safety by leveraging tools and technologies and interpreting developments in regulatory compliance. The 7thinstallment of Pharmacovigilance, Drug Safety & Risk Management will focus on improving PV strategies to enable predictive drug safety in order to increase patient safety, and decrease drug risk potential.
Develop more proficient and profound pharmacovigilance strategies to utilize throughout product lifecycle. Streamline drug safety and regulatory approval process and increase patient voluntary reporting.
tbc Philadelphia, PA, United States of America
http://www.marcusevans-conferences-northamerican.com/marcusevans-conferences-event-details.asp?EventID=23641#.WUlJVZDyvct
Biosimilars & Biobetters 2017
27 September 2017 - 28 September 2017
SMi Group are thrilled to present the 2017 8th annual conference on Biosimilars & Biobetters taking place on 27th & 28th September in Central London, UK.
As the patents for several innovator biologics expire, biopharmaceutical companies are taking the opportunity to develop more affordable forms creating a rapidly booming biosimilars market. However, as the field of biosimilars evolves, challenges in immunogenicity studies, securing market share, exclusivity and regulations still persist.
Join us this autumn to arm yourself with the key requirements and tools for successful market entry through strategic direction on commercialisation; insight into potential therapeutic areas; and critical updates on interchangeability guidelines and patient litigation.
A must attend for principle scientists and regulatory experts involved in biotechnology, market access and compliance, Biosimilars & Biobetters 2017 will capture expert insight by honing in on current market trends through to emerging opportunities and global developments.
THE NOTABLE SPEAKER LINE-UP WILL INCLUDE:
• Bernd Liedert, Senior Clinical Program Leader Biosimilars, Boehringer Ingelheim
• Ho-Ung Kim, Division Head Strategy and Operations, Celltrion Healthcare
• Sarah Rickwood, Vice President, Head of European Thought Leadership, QuintilesIMS
• Matthew Turner, Global Medical Director, Biosimilars, Merck Group
• Steiner Madsen, Medical Director, Norwegian Medicines Agency
• Thomas Sachnik, Senior Manager Strategic Associate to the President & CEO Generics Europe, Teva Pharmaceuticals
• Harish Pai, Principal Scientific Manager, Biocon
• Ildiko Aradi, Head Clinical Development of Biologics, Gedeon Richter
• Glenn Kazo, President & COO, Prolong Pharmaceuticals
• Richard Peck, Vice President Regulatory Affairs, Lupin Europe
INDUSTRY LEVERAGE AT BIOSIMILARS & BIOBETTERS 2017:
• Gain an overview of the latest developments in regulation to increase speed of entry and compliance through informed guidance on interchangeability laws, patient litigation and IP rules
• Develop strategies for market access and expansion by identifying key changes and future projections in biosimilars
• Evolve clinical developments through insight into orphan drugs, in-vitro functional assays and data extrapolation
• Create a competitive edge through understanding the multifaceted field of "switching studies"
• Hear case studies on biosimilars drug development from pre-clinical to clinical and the various testing required such as immunogenicity and bio-similarity tests
• Discuss challenges and potential solutions in exclusivity and HCP acceptance
• Get unique coverage of biobetters from companies specialising in this field
Holiday Inn Kensington Forum, London, UK
http://www.smi-online.co.uk/pharmaceuticals/uk/biosimilars-and-biobetters?utm_medium=www.biosimilars-europe.com&utm_source=P-222&utm_campaign=ddiscovery
Autoimmune and Inflammation Drug Targets
27 September 2017 - 28 September 2017
Many autoimmune and immune-related inflammation disorders are chronic conditions for which the development of orally-delivered therapeutics, usually small-molecule-based, is a sought-after goal because of their convenience of administration and lower cost to the patient, especially for a potentially lifelong therapy. While much progress in the field of immunotherapy has been made with injectable, protein-based therapeutics such as biologics, those therapeutic modalities can only act on cell surface proteins. However, a wealth of new knowledge of immune-related intracellular signaling pathways, partly spurred by the success of biologics, is revealing new intracellular targets against which cell-penetrable therapeutics can be developed. Cambridge Healthtech Institute’s 2nd Annual Autoimmune and Inflammation Drug Targets conference will cover the advancement of promising oral-based drug candidates and emerging intracellular drug targets for combatting autoimmune and inflammatory disease.
The Weston Copley Place, Boston, MA, USA
http://www.discoveryontarget.com/discoveryontarget_homepage.aspx
6th Annual Cancer Vaccines Conference
27 September 2017 - 28 September 2017
SMi Group is thrilled to present the 6th annual Cancer Vaccines conference, taking place on 27th & 28th September 2017 in Central London, UK. Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.
Aimed at an audience of senior scientists and oncology specialists involved in targeted vaccines and drug research, Cancer Vaccines 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of cancer immunotherapy. The 6th annual show will capture expert insight by honing in on new pathways with novel vaccines and immunotherapies, drug formulations, personalised treatment, immune check-point inhibitors, plus more.
Join us this September for strategic direction on vaccine commercialisation and arm yourself with the key requirements and tools for successful vaccine development through informed guidance delivered by a top panel of speakers.
Copthorne Tara Hotel, Scarsdale Place, Kensington, London, UK
http://www.cancervaccinesevent.com/DDT